Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism

Gabriel Frampton, Pietro Invernizzi, Francesca Bernuzzi, Hae Yong Pae, Matthew Quinn, Darijana Horvat, Cheryl Galindo, Li Huang, Matthew McMillin, Brandon Cooper, Lorenza Rimassa, Sharon DeMorrow

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Background and objectives: Cholangiocarcinoma is a devastating cancer of biliary origin with limited treatment options. The growth factor, progranulin, is overexpressed in a number of tumours. The study aims were to assess the expression of progranulin in cholangiocarcinoma and to determine its effects on tumour growth. Methods The expression and secretion of progranulin were evaluated in multiple cholangiocarcinoma cell lines and in clinical samples from patients with cholangiocarcinoma. The role of interleukin 6 (IL-6)-mediated signalling in the expression of progranulin was assessed using a combination of specific inhibitors and shRNA knockdown techniques. The effect of progranulin on proliferation and Akt activation and subsequent effects of FOXO1 phosphorylation were assessed in vitro. Progranulin knockdown cell lines were established, and the effects on cholangiocarcinoma growth were determined. Results: Progranulin expression and secretion were upregulated in cholangiocarcinoma cell lines and tissue, which were in part via IL-6-mediated activation of the ERK1/2/RSK1/C/EBPβ pathway. Blocking any of these signalling molecules, by either pharmacological inhibitors or shRNA, prevented the IL-6-dependent activation of progranulin expression. Treatment of cholangiocarcinoma cells with recombinant progranulin increased cell proliferation in vitro by a mechanism involving Akt phosphorylation leading to phosphorylation and nuclear extrusion of FOXO1. Knockdown of progranulin expression in cholangiocarcinoma cells decreased the expression of proliferating cellular nuclear antigen, a marker of proliferative capacity, and slowed tumour growth in vivo. Conclusions: Evidence is presented for a role for progranulin as a novel growth factor regulating cholangiocarcinoma growth. Specific targeting of progranulin may represent an alternative for the development of therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)268-277
Number of pages10
JournalGut
Volume61
Issue number2
DOIs
StatePublished - Feb 2012
Externally publishedYes

Fingerprint

Cholangiocarcinoma
Interleukin-6
Growth
Phosphorylation
Cell Line
Small Interfering RNA
Neoplasms
Intercellular Signaling Peptides and Proteins
Nuclear Antigens
Therapeutics
Cell Proliferation
Pharmacology

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Frampton, G., Invernizzi, P., Bernuzzi, F., Pae, H. Y., Quinn, M., Horvat, D., ... DeMorrow, S. (2012). Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. Gut, 61(2), 268-277. https://doi.org/10.1136/gutjnl-2011-300643

Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. / Frampton, Gabriel; Invernizzi, Pietro; Bernuzzi, Francesca; Pae, Hae Yong; Quinn, Matthew; Horvat, Darijana; Galindo, Cheryl; Huang, Li; McMillin, Matthew; Cooper, Brandon; Rimassa, Lorenza; DeMorrow, Sharon.

In: Gut, Vol. 61, No. 2, 02.2012, p. 268-277.

Research output: Contribution to journalArticle

Frampton, G, Invernizzi, P, Bernuzzi, F, Pae, HY, Quinn, M, Horvat, D, Galindo, C, Huang, L, McMillin, M, Cooper, B, Rimassa, L & DeMorrow, S 2012, 'Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism', Gut, vol. 61, no. 2, pp. 268-277. https://doi.org/10.1136/gutjnl-2011-300643
Frampton, Gabriel ; Invernizzi, Pietro ; Bernuzzi, Francesca ; Pae, Hae Yong ; Quinn, Matthew ; Horvat, Darijana ; Galindo, Cheryl ; Huang, Li ; McMillin, Matthew ; Cooper, Brandon ; Rimassa, Lorenza ; DeMorrow, Sharon. / Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism. In: Gut. 2012 ; Vol. 61, No. 2. pp. 268-277.
@article{6312bf9f6c0e4a6a89e3360b6fb8732e,
title = "Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism",
abstract = "Background and objectives: Cholangiocarcinoma is a devastating cancer of biliary origin with limited treatment options. The growth factor, progranulin, is overexpressed in a number of tumours. The study aims were to assess the expression of progranulin in cholangiocarcinoma and to determine its effects on tumour growth. Methods The expression and secretion of progranulin were evaluated in multiple cholangiocarcinoma cell lines and in clinical samples from patients with cholangiocarcinoma. The role of interleukin 6 (IL-6)-mediated signalling in the expression of progranulin was assessed using a combination of specific inhibitors and shRNA knockdown techniques. The effect of progranulin on proliferation and Akt activation and subsequent effects of FOXO1 phosphorylation were assessed in vitro. Progranulin knockdown cell lines were established, and the effects on cholangiocarcinoma growth were determined. Results: Progranulin expression and secretion were upregulated in cholangiocarcinoma cell lines and tissue, which were in part via IL-6-mediated activation of the ERK1/2/RSK1/C/EBPβ pathway. Blocking any of these signalling molecules, by either pharmacological inhibitors or shRNA, prevented the IL-6-dependent activation of progranulin expression. Treatment of cholangiocarcinoma cells with recombinant progranulin increased cell proliferation in vitro by a mechanism involving Akt phosphorylation leading to phosphorylation and nuclear extrusion of FOXO1. Knockdown of progranulin expression in cholangiocarcinoma cells decreased the expression of proliferating cellular nuclear antigen, a marker of proliferative capacity, and slowed tumour growth in vivo. Conclusions: Evidence is presented for a role for progranulin as a novel growth factor regulating cholangiocarcinoma growth. Specific targeting of progranulin may represent an alternative for the development of therapeutic strategies.",
author = "Gabriel Frampton and Pietro Invernizzi and Francesca Bernuzzi and Pae, {Hae Yong} and Matthew Quinn and Darijana Horvat and Cheryl Galindo and Li Huang and Matthew McMillin and Brandon Cooper and Lorenza Rimassa and Sharon DeMorrow",
year = "2012",
month = "2",
doi = "10.1136/gutjnl-2011-300643",
language = "English (US)",
volume = "61",
pages = "268--277",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Interleukin-6-driven progranulin expression increases cholangiocarcinoma growth by an Akt-dependent mechanism

AU - Frampton, Gabriel

AU - Invernizzi, Pietro

AU - Bernuzzi, Francesca

AU - Pae, Hae Yong

AU - Quinn, Matthew

AU - Horvat, Darijana

AU - Galindo, Cheryl

AU - Huang, Li

AU - McMillin, Matthew

AU - Cooper, Brandon

AU - Rimassa, Lorenza

AU - DeMorrow, Sharon

PY - 2012/2

Y1 - 2012/2

N2 - Background and objectives: Cholangiocarcinoma is a devastating cancer of biliary origin with limited treatment options. The growth factor, progranulin, is overexpressed in a number of tumours. The study aims were to assess the expression of progranulin in cholangiocarcinoma and to determine its effects on tumour growth. Methods The expression and secretion of progranulin were evaluated in multiple cholangiocarcinoma cell lines and in clinical samples from patients with cholangiocarcinoma. The role of interleukin 6 (IL-6)-mediated signalling in the expression of progranulin was assessed using a combination of specific inhibitors and shRNA knockdown techniques. The effect of progranulin on proliferation and Akt activation and subsequent effects of FOXO1 phosphorylation were assessed in vitro. Progranulin knockdown cell lines were established, and the effects on cholangiocarcinoma growth were determined. Results: Progranulin expression and secretion were upregulated in cholangiocarcinoma cell lines and tissue, which were in part via IL-6-mediated activation of the ERK1/2/RSK1/C/EBPβ pathway. Blocking any of these signalling molecules, by either pharmacological inhibitors or shRNA, prevented the IL-6-dependent activation of progranulin expression. Treatment of cholangiocarcinoma cells with recombinant progranulin increased cell proliferation in vitro by a mechanism involving Akt phosphorylation leading to phosphorylation and nuclear extrusion of FOXO1. Knockdown of progranulin expression in cholangiocarcinoma cells decreased the expression of proliferating cellular nuclear antigen, a marker of proliferative capacity, and slowed tumour growth in vivo. Conclusions: Evidence is presented for a role for progranulin as a novel growth factor regulating cholangiocarcinoma growth. Specific targeting of progranulin may represent an alternative for the development of therapeutic strategies.

AB - Background and objectives: Cholangiocarcinoma is a devastating cancer of biliary origin with limited treatment options. The growth factor, progranulin, is overexpressed in a number of tumours. The study aims were to assess the expression of progranulin in cholangiocarcinoma and to determine its effects on tumour growth. Methods The expression and secretion of progranulin were evaluated in multiple cholangiocarcinoma cell lines and in clinical samples from patients with cholangiocarcinoma. The role of interleukin 6 (IL-6)-mediated signalling in the expression of progranulin was assessed using a combination of specific inhibitors and shRNA knockdown techniques. The effect of progranulin on proliferation and Akt activation and subsequent effects of FOXO1 phosphorylation were assessed in vitro. Progranulin knockdown cell lines were established, and the effects on cholangiocarcinoma growth were determined. Results: Progranulin expression and secretion were upregulated in cholangiocarcinoma cell lines and tissue, which were in part via IL-6-mediated activation of the ERK1/2/RSK1/C/EBPβ pathway. Blocking any of these signalling molecules, by either pharmacological inhibitors or shRNA, prevented the IL-6-dependent activation of progranulin expression. Treatment of cholangiocarcinoma cells with recombinant progranulin increased cell proliferation in vitro by a mechanism involving Akt phosphorylation leading to phosphorylation and nuclear extrusion of FOXO1. Knockdown of progranulin expression in cholangiocarcinoma cells decreased the expression of proliferating cellular nuclear antigen, a marker of proliferative capacity, and slowed tumour growth in vivo. Conclusions: Evidence is presented for a role for progranulin as a novel growth factor regulating cholangiocarcinoma growth. Specific targeting of progranulin may represent an alternative for the development of therapeutic strategies.

UR - http://www.scopus.com/inward/record.url?scp=84855170282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855170282&partnerID=8YFLogxK

U2 - 10.1136/gutjnl-2011-300643

DO - 10.1136/gutjnl-2011-300643

M3 - Article

C2 - 22068162

AN - SCOPUS:84855170282

VL - 61

SP - 268

EP - 277

JO - Gut

JF - Gut

SN - 0017-5749

IS - 2

ER -